Dexcom Touts G7 As ‘The Most Accurate CGM’ As It Prepares For US Launch
The US FDA has granted authorization to Dexcom to market its G7 continuous glucose monitor, which the company will launch in the next couple of months.
You may also be interested in...
In this first of a series of Exec Chats with leaders at major diabetes companies presenting at ADA’s Scientific Sessions 2023, CEO Kevin Sayer discusses Dexcom’s ambitious R&D map to expand into metabolic health and develop innovative new products for diabetes and consumer markets.
The reimbursement expansion for Abbott’s FreeStyle Libre 2 for basal insulin bodes well for continued basal coverage expansion into other geographies and commercial payers.
The company’s cash balance at the end of last quarter was more than enough to weather most storms – so why has Dexcom raised more money?